Emerging Market Outsourcing Report - Q3 2026
Summary
This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q3 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and packaging (clinical and commercial) for countries in emerging markets.Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A1 Biochem Labs (India) Private Limited
- Aarti Drugs Ltd
- Alivus Life Sciences Ltd
- Apitoria Pharma Pvt Ltd
- Aragen Life Sciences Ltd
- Asymchem Laboratories Tianjin Co Ltd
- Ashland Inc
- AstraZeneca
- Auriga Research Pvt. Ltd.
- Aurisco Pharmaceutical Co Ltd
- Aurobindo Pharma Ltd
- Axplora Group GmbH
- Bajaj Healthcare Ltd
- Bestchrom
- Biodeal Pharmaceuticals Pvt Ltd
- BioKangtai
- Boehringer Ingelheim Pharmaceuticals
- BratskKhimSintez
- Caplin Point Laboratories Ltd
- Capworks Investment Manager India Private Limited
- Citeline
- Cognizant
- Cohance Lifesciences Ltd
- Concord Biotech Ltd
- Corona Remedies Ltd
- Crystal Pharmatech Co Ltd
- CSPC Pharmaceutical Group
- CuraTeQ Biologics Pvt Ltd
- Dr. Reddy's Laboratories Ltd
- Esco Aster Bioengineering
- Farmabios
- Formycon AG
- Fujian Genohope Biotechnology Co Ltd
- Fusix Biotech Gmbh
- Gland Pharma Ltd
- GlobalData Plc
- Gopaldas Visram & Co Ltd
- GSK
- Henkang Pharma
- Hubei Gedian Humanwell Pharmaceutical Co Ltd
- Indoco Remedies Ltd
- Infinata
- IPCA Laboratories Ltd
- Jackson Laboratories Pvt Ltd
- Jefferies
- Jilin Asymchem Pharmaceuticals Co Ltd
- Johnson & Johnson
- Krebs Biochemicals & Industries Ltd
- Maiva Pharma Pvt Ltd
- Mergermarket
- Morepen Laboratories Ltd
- Neuland Laboratories Ltd
- Novo AS
- OneSource Specialty Pharma Ltd
- Orchem Products
- Pharmasyntez
- Piramal Pharma Ltd
- Porton Advanced Solution ltd
- Qilu Pharmaceutical (Hainan) Co Ltd
- Qilu Pharmaceutical Co Ltd
- Recipharm Pharmaservice s Pvt Ltd
- Renaissance Pharma Ltd
- RMB Capitalworks
- Sai Life Sciences
- Santa Farma Ilac Sanayii AS
- Shanghai Asymchem Biotechnology Co Ltd
- Shantha Biologics Pvt Ltd
- Sichuan Renan Pharmaceutical Co Ltd
- Strides Pharma Science Ltd
- Suzhou Hillhouse Qirui Medical Health Industry Investment Partnership
- Viwit Pharmaceutical Co Ltd
- Wanbury Ltd
- WuXi AppTec Co Ltd
- WuXi Biologics
- Yapan Bio Pvt Ltd
- Zhejiang Hengkang Pharmaceutical Co Ltd
- 2Y-Biopharma Ltd

